Investing.com -- Celcuity Inc. (NASDAQ: CELC) stock rose 5.2% after the clinical-stage biotechnology company announced it will hold a conference call on Monday, July 28, 2025, to reveal topline ...

New clinical trials are advancing treatments for cutaneous T-cell lymphoma, advanced solid tumors, pediatric sarcomas and ALK ...

The trial will test several treatment approaches in the maintenance setting for extensive stage small cell lung cancer.

Context Therapeutics Inc. (NASDAQ: CNTX) is one of the best penny stocks under $1 to buy now. Earlier in June, Context ...

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

Topline data were announced from a phase 3 clinical program evaluating anselamimab in patients with Mayo stages 3a and 3b light chain (AL) amyloidosis.

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

A high dose of centanafadine was shown to be safe and effective at lowering ADHD symptoms for adolescents, according to ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...